针对基层医疗循证指标的可适配实施包:一项实用整群随机评估
该研究在英格兰西约克郡144家全科诊所开展两项平行实用整群随机试验,比较可适配实施包对四项循证质量指标依从性的影响。实施包降低了风险处方(OR 0.82),但对糖尿病控制、血压控制和房颤抗凝治疗无足够证据显示有效。
要点
- 实施包降低风险处方,OR 0.82(97.5%CI 0.67-0.99)。
- 糖尿病控制、血压控制及抗凝处方未见显著改善。
- 对≥65岁患者无胃保护联用阿司匹林和氯吡格雷有降低。
核心结论
- 多组分实施包对医生可控的处方行为具有临床和成本效果,但对需患者参与的复杂行为效果不足。
研究设计与样本
- 在英格兰西约克郡全科诊所开展两项平行实用整群随机试验,采用平衡不完全区组设计。
- 2015年4月随机分配80家诊所至试验1(40家/臂)、64家至试验2(32家/臂)。
- 采用意向性分析(ITT),调整患者水平和诊所水平潜在混杂因素。
主要发现
- 风险处方降低:OR 0.82(97.5%CI 0.67-0.99,p=0.017)。
- 糖尿病控制:OR 1.03(97.5%CI 0.89-1.18,p=0.693)。
- 血压控制:OR 1.05(97.5%CI 0.96-1.16,p=0.215)。
- 抗凝处方:OR 0.90(97.5%CI 0.75-1.09,p=0.214)。
- ≥65岁患者无胃保护联用阿司匹林和氯吡格雷降低:调整OR 0.62(97.5%CI 0.39-0.99,p=0.021)。
关键数值与推荐
- 风险处方的增量成本效果比为每质量调整生命年(QALY)£1,359。
- 主要终点为11个月时患者水平指标。
临床怎么用
- 可优先将多组分实施包用于针对处方行为的质量改进。
- 对需患者参与的复杂行为(如糖尿病控制)需额外策略。
局限性
- 无法推断实施包中各组分相对效应。
- 糖尿病控制的复合终点可能过于难以达到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In primary care, multiple priorities and system pressures make closing the gap between evidence and practice challenging. Most implementation studies focus on single conditions, limiting generalisability. We compared an adaptable implementation package against an implementation control and assessed effects on adherence to four different evidence-based quality indicators. METHODS AND FINDINGS: We undertook two parallel, pragmatic cluster-randomised trials using balanced incomplete block designs in general practices in West Yorkshire, England. We used 'opt-out' recruitment, and we randomly assigned practices that did not opt out to an implementation package targeting either diabetes control or risky prescribing (Trial 1); or blood pressure (BP) control or anticoagulation in atrial fibrillation (AF) (Trial 2). Within trials, each arm acted as the implementation control comparison for the other targeted indicator. For example, practices assigned to the diabetes control package acted as the comparison for practices assigned to the risky prescribing package. The implementation package embedded behaviour change techniques within audit and feedback, educational outreach, and computerised support, with content tailored to each indicator. Respective patient-level primary endpoints at 11 months comprised the following: achievement of all recommended levels of haemoglobin A1c (HbA1c), BP, and cholesterol; risky prescribing levels; achievement of recommended BP; and anticoagulation prescribing. Between February and March 2015, we recruited 144 general practices collectively serving over 1 million patients. We stratified computer-generated randomisation by area, list size, and pre-intervention outcome achievement. In April 2015, we randomised 80 practices to Trial 1 (40 per arm) and 64 to Trial 2 (32 per arm). Practices and trial personnel were not blind to allocation. Two practices were lost to follow-up but provided some outcome data. We analysed the intention-to-treat (ITT) population, adjusted for potential confounders at patient level (sex, age) and practice level (list size, locality, pre-intervention achievement against primary outcomes, total quality scores, and levels of patient co-morbidity), and analysed cost-effectiveness. The implementation package reduced risky prescribing (odds ratio [OR] 0.82; 97.5% confidence interval [CI] 0.67-0.99, p = 0.017) with an incremental cost-effectiveness ratio of £1,359 per quality-adjusted life year (QALY), but there was insufficient evidence of effect on other primary endpoints (diabetes control OR 1.03, 97.5% CI 0.89-1.18, p = 0.693; BP control OR 1.05, 97.5% CI 0.96-1.16, p = 0.215; anticoagulation prescribing OR 0.90, 97.5% CI 0.75-1.09, p = 0.214). No statistically significant effects were observed in any secondary outcome except for reduced co-prescription of aspirin and clopidogrel without gastro-protection in patients aged 65 and over (adjusted OR 0.62; 97.5% CI 0.39-0.99; p = 0.021). Main study limitations concern our inability to make any inferences about the relative effects of individual intervention components, given the multifaceted nature of the implementation package, and that the composite endpoint for diabetes control may have been too challenging to achieve. CONCLUSIONS: In this study, we observed that a multifaceted implementation package was clinically and cost-effective for targeting prescribing behaviours within the control of clinicians but not for more complex behaviours that also required patient engagement. TRIAL REGISTRATION: The study is registered with the ISRCTN registry (ISRCTN91989345).
引用
- Willis TA, Collinson M, Glidewell L, et al. An adaptable implementation package targeting evidence-based indicators in primary care: A pragmatic cluster-randomised evaluation. PLoS Med. 2020. PMID: 32109257. doi:10.1371/journal.pmed.1003045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。